10.07.2012 - Evotec has announced a license and collaboration agreement with Janssen Pharmaceuticals on a portfolio of small molecules and biologics.
The subsidiary of Johnson & Johnson targets a novel academic-biotech collaboration called CureBeta built around a portfolio of diabetes treatments in regenerative medicine put together in the lab of Harvard scientist Douglas Melton. The pharma pays a modest upfront of US$8m for the rights but promised to pay US$300m in milestones per programme. J&J receives the global exclusive rights to the programmes, which involve insulin-producing beta cells. Harvard and Evotec agreed to share profits. In the first stage of the collaboration, Harvard, the Howard Hughes Medical Institute and the Germanbiotech Evotec worked on new assays and tools for regenerating beta cells. With the help of J&J's research expertise, the partners hope to make all stages until approval. The appearance of a big pharma completes the alliance that comprised only academic researchers and a biotech company. "We have not only achieved our scientific goals of creating a superior beta cell drug discovery platform and generating a deep pipeline of novel and exciting targets, but we have also established a new model of collaboration between academia and industry that has proven highly efficient and effective in accelerating innovative scientific development," said Dr. Cord Dohrmann, the CSO at Evotec. Elmar Kraus, analyst at DZ Bank said: "Evotec promised and delivered a research and development alliance with one of the big players inthe field in the already huge and growing indication of diabetes. With this, the CureBeta initiative, established in 2011 with the Howard Hughes Medical Institute (HHMI) at Harvard has already paid off." Evotec shares rose 18% at the German Stock Exchange in Frankfurt.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more